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Summary
Background Limited treatment options have been available for people with HIV who have had virological failure of the 
three original classes of HIV antiretroviral drugs—so-called triple-class virological failure (TCVF). However, 
introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological 
and clinical outcomes for individuals with TCVF in 2000–09.
Methods In our cohort study, we analysed data for adults starting antiretroviral therapy from 1998 in cohorts 
participating in the PLATO II project, which is part of COHERE, a colla boration of European cohorts. TCVF was 
defi ned as virological failure to at least two nucleoside reverse transcriptase inhibitors, one non-nucleoside reverse-
transcriptase inhibitor, and one ritonavir-boosted protease inhibitor, with virological failure of a drug defi ned as one 
viral-load measurement of greater than 500 copies per mL after at least 4 months of continuous use. We used 
multivariable generalised estimating equation logistic models and Poisson regression models to study trends in 
virological suppression and incidence of AIDS or death after TCVF. We adjusted for sex, transmission group, age, 
AIDS status, CD4 cell count, plasma viral loads at TCVF, achievement of virological response (<50 copies per mL), 
and number of drug failures before TCVF.
Findings 28 of 33 cohorts in COHERE contributed data to the PLATO II project, of which four had no participants 
eligible for inclusion in this study. 2476 (3%) of 91 764 participants from the remaining 24 cohorts had TCVF and at 
least one viral load measurement in 2000–09. The proportion of patients with virological response after TCVF 
increased from 19·5% in 2000 to 57·9% in 2009 (adjusted p<0·0001). Incidence of AIDS decreased from 
7·7 per 100 person-years in 2000–02 to 2·3 in 2008 and 1·2 in 2009 (adjusted p<0·0001). Mortality decreased from 
4·0 per 100 person-years between 2000 and 2002 to 1·9 in 2007 and 1·4 in 2008 (unadjusted p=0·023), but the trend 
was not signifi cant after adjustment (p=0·22).
Interpretation A substantial improvement in viral load suppression and accompanying decrease in the rates of AIDS 
in people after extensive failure to drugs from the three original antiretroviral classes during 2000–09 was probably 
mainly driven by availability of newer drugs with better tolerability and ease of use and small cross-resistance profi les, 
suggesting the public health benefi t of the introduction of new drugs.
Funding UK Medical Research Council.
Introduction
Investi gations of immunological and clinical outcomes 
for patients after virological failure to all three original 
antiretroviral classes1–4 have shown the eff ects of 
widespread antiviral resistance on prognosis,4 the 
importance of maintaining CD4 cell counts of 200 cells 
per μL or higher,2 and the need to continue antiretroviral 
therapy even when viral load is not controlled.2,5,6 
Improved clinical outcomes were reported in individuals 
with triple-class virological failure (TCVF) dependent 
on the number of new drugs started, probably owing to 
more favourable resistance profi les.1,3 However, most 
people in these early studies started antiretroviral 
therapy with only one or two drugs, which conferred a 
high risk of resistance to nucleoside reverse-
transcriptase inhibitors (NRTIs). Now, all patients 
starting anti retroviral therapy are recommended to do 
so with potent combination regimens of three or 
more drugs.
Although current regimens have led to sustained viral 
suppression in an increasing proportion of people,7 some 
individuals do still have virological failure to drugs from 
the three original classes. As part of the Pursuing Later 
Treatment Option II (PLATO II) project, we reported a low 
rate of TCVF (3·4% by 5 years)8 in participants in the 
Collaboration of Observational HIV Epidemiological 
Research Europe (COHERE) database who started anti-
retroviral therapy including a non-NTRI (NNRTI) or a 
ritonavir-boosted protease inhibitor from 1998. Virological 
and clinical outcomes for people who had TCVF, and in 
particular how these outcomes changed with time, have 
not been widely studied.9 We aimed to assess trends in 
virological and clinical outcomes over the past decade in 
people with TCVF.
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Methods
Study design and procedures
We analysed data obtained from participants in the 
PLATO II project from the COHERE database10 (a 
collaboration of 33 observational cohort studies of HIV 
in Europe). The PLATO II project contains data from 
28 participating cohorts, which submit information in a 
standardised format11 to one of two regional coordinating 
centres, where error checks are done before data are 
merged into cohort data and added to COHERE. 
Duplicate records from people in more than one cohort 
were removed. We analysed data added to the COHERE 
database as part of the PLATO II project in 2010 for 
previously untreated participants aged 16 or older who 
started antiretroviral therapy from 1998.
We defi ned virological failure of a drug as plasma HIV-1 
RNA loads of more than 500 copies per mL despite 
4 months or more of continuous use, irrespective of 
concomitant use of other drugs in this timeframe. 
Virological failure of drugs from all three classes was 
defi ned as virological failure of two NRTIs, one NNRTI, 
and one ritonavir-boosted protease inhibitor. We refer to 
this combination as TCVF, although other drugs within 
these classes might retain antiviral activity (eg, newer 
protease inhibitors, such as darunavir, and NNRTIs, such 
as etravirine, which were designed to be not cross-
resistant to existing drugs in the class). We included 
patients with TCVF from 2000 onwards in the present 
analysis if they had at least one plasma viral-load 
measurement after TCVF between 2000 and 2009.
Statistical analysis
We calculated the proportion of people with virological 
response (<50 copies per mL) after TCVF for the year 
2000–09, using values recorded closest to July 1 for each 
patient. We assessed trends in viral suppression adjusted 
for characteristics of people at the time of TCVF that 
could aff ect the probability of virological response by 
fi tting a multivariable logistic regression model. We 
adjusted for sex, transmission group, age, presence of 
AIDS, CD4 cell count, plasma viral load at TCVF, previous 
achievement of virological response, and number of drug 
failures before TCVF. For the adjusted analysis of 
virological response, we included all plasma HIV RNA 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Individuals in follow-up 41 192 368 594 848 1138 1415 1561 1609 795
Age (years) 37 (32–40) 39 (33–44) 39 (34–44) 39 (35–44) 40 (35–45) 41 (36–46) 41 (36–47) 42 (37–47) 43 (38–48) 43 (38–49)
Year of TCVF development 2000 
(2000–2000)
2001 
(2000–2001)
2001 
(2001–2002)
2002 
(2001–2003)
2003 
(2002–2004)
2004 
(2002–2004)
2004 
(2003–2005)
2005
(2003–2006)
2005 
(2004–2007)
2006 
(2004–2007)
Years since start of antiretroviral 
therapy
2 (1–2) 3 (2–3) 3 (3–4) 4 (3–5) 5 (4–6) 6 (4–7) 7 (5–8) 8 (6–9) 8 (6–10) 9 (7–11)
Group
Men who have sex with men 18 (44%) 79 (41%) 119 (32%) 188 (32%) 251 (30%) 356 (31%) 419 (30%) 466 (30%) 482 (30%) 233 (29%)
Heterosexual men 4 (10%) 24 (13%) 70 (19%) 121 (20%) 186 (22%) 241 (21%) 307 (22%) 331 (21%) 337 (21%) 165 (21%)
Heterosexual women 9 (22%) 40 (21%) 73 (20%) 116 (20%) 180 (21%) 257 (23%) 343 (24%) 407 (26%) 422 (26%) 180 (23%)
Injecting-drug users 5 (12%) 30 (16%) 67 (18%) 101 (17%) 135 (16%) 166 (15%) 201 (14%) 204 (13%) 208 (13%) 126 (16%)
Other or unknown 5 (12%) 19 (10%) 39 (11%) 68 (11%) 96 (11%) 118 (10%) 145 (10%) 153 (10%) 160 (10%) 91 (11%)
Individuals with AIDS before TCVF 19 (46%) 88 (46%) 156 (42%) 254 (43%) 352 (42%) 465 (41%) 540 (38%) 599 (38%) 605 (38%) 338 (43%)
Antiretroviral therapy received
At least one PI/r 32 (78%) 145 (76%) 264 (72%) 444 (75%) 686 (81%) 913 (80%) 1182 (84%) 1320 (85%) 1322 (82%) 647 (81%)
At least one NNRTI 20 (49%) 65 (34%) 91 (25%) 131 (22%) 157 (19%) 181 (16%) 192 (14%) 205 (13%) 219 (14%) 130 (16%)
At least two NRTIs 33 (80%) 160 (83%) 301 (82%) 485 (82%) 676 (80%) 920 (81%) 1166 (82%) 1286 (82%) 1295 (81%) 634 (80%)
At least four drugs 21 (51%) 60 (31%) 94 (26%) 156 (26%) 206 (24%) 260 (23%) 315 (22%) 350 (22%) 345 (21%) 163 (21%)
At least one new drug* 0 4 (2%) 8 (2%) 40 (7%) 218 (26%) 408 (36%) 624 (44%) 661 (42%) 789 (49%) 415 (52%)
At least two new drugs* 0 0 1 (<1%) 3 (<1%) 18 (2%) 30 (3%) 46 (3%) 67 (4%) 133 (8%) 86 (11%)
Darunavir 0 0 0 0 0 5 (<1%) 38 (3%) 92 (6%) 182 (11%) 117 (15%)
Enfuvirtide 0 4 (2%) 5 (1%) 11 (2%) 43 (5%) 55 (5%) 70 (5%) 62 (4%) 31 (2%) 13 (2%)
Etravirine 0 0 0 0 1 (<1%) 1 (<1%) 1 (<1%) 11 (<1%) 43 (3%) 35 (4%)
Maraviroc 0 0 0 0 0 1 (<1%) 3 (<1%) 3 (<1%) 15 (<1%) 16 (2%)
Raltegravir 0 0 0 0 0 1 (<1%) 3 (<1%) 32 (2%) 151 (9%) 92 (12%)
Tipranavir 0 0 1 (<1%) 11 (2%) 13 (2%) 31 (3%) 38 (3%) 25 (2%) 15 (<1%) 2 (<1%)
Atazanavir 0 0 3 (<1%) 21 (4%) 179 (21%) 345 (30%) 518 (37%) 519 (33%) 528 (33%) 253 (32%)
None 3 (7%) 9 (5%) 19 (5%) 33 (6%) 42 (5%) 68 (6%) 65 (5%) 72 (5%) 71 (4%) 28 (4%)
Data are n (%) or median (IQR). TCVF=triple-class virological failure. NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside reverse transcriptase inhibitor. PI/r=ritonavir-boosted protease 
inhibitor. *Darunavir, enfuvirtide, etravirine, maraviroc, raltegravir, tipranavir, or atazanavir.
Table 1: Characteristics of individuals with TCVF in follow-up in the specifi ed year
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measurements obtained for all people after TCVF. 
Because viral load was a repeated measurement, we used 
generalised estimating equation models with an 
exchangeable covariance matrix. Notably, because our 
objective was mainly descriptive, we did not attempt to 
further adjust for time-dependent variables such as access 
to new drugs or improvements in adherence.
We estimated trends in incidence per person-year of 
new AIDS-defi ning events (fi rst new diagnosis of AIDS 
since diagnosis of TCVF, which might or might not be 
the fi rst AIDS disease) between 2000 and 2009 and in 
death rates between 2000 and 2008. We used the 
European defi nition of AIDS,12 corresponding to the 
clinical part of the US Centers for Disease Control and 
Prevention defi nition. Person-years of follow-up were 
censored 6 months after the last measurement of CD4 cell 
count or viral load, the end of the year used in the 
analysis, or on Dec 31, 2009, whichever occurred fi rst. 
For incidence of AIDS, follow-up was censored at death. 
For death, follow-up was censored on Jan 1, 2009, because 
otherwise records might have been incomplete for some 
cohorts. Thus, we only report death rates to 2008. We 
used multivariable Poisson regression models to assess 
the trends in the risk of AIDS or death in people with 
TCVF, with the same covariates as we used for the 
analysis of viral load. Patient-years with missing CD4 
counts were excluded from the analyses.
All tests of signifi cance were two-sided, and p<0·05 
was regarded as signifi cant. Analyses were done with 
SAS software version 9.1 and Stata software version 11.0.
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. Dominique Costagliola, Rebecca Lodwick, 
Bruno Ledergerber, and Andrew Phillips had full access 
to all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
Two of 28 cohorts in the PLATO II project were paediatric 
cohorts not included in this analysis. We also excluded 
two cohorts that had few data for patients aged 16 years or 
older starting combined antiretroviral therapy and no 
data for patients with TCVF. By 2010, the PLATO II project 
contained data for 91 764 individuals, of whom 2722 (3%) 
had TCVF. Overall, 2709 (>99%) of 2722 people with 
TCVF in included cohorts had failure in 2000–09, and 
2476 (91%) had at least one viral-load measurement after 
TCVF in this time. 1665 (67%) patients were men, 703 
(28%) were men who have sex with men, 528 (21%) were 
heterosexual men, 637 (26%) were heterosexual women, 
and 354 (14%) were injecting drug users. At time of TCVF, 
the median age was 39·5 years (IQR 34·4–45·2), median 
viral load was 4·0 log10 copies per mL (3·2–4·8), and 
median CD4 cell count was 270 cells per μL (147–430). 
936 (38%) of 2476 people had had an AIDS defi ning event. 
Figure: 2000–09 trends in virological and clinical outcomes in people with triple-class virological failure
(A) Individuals with plasma HIV-1 RNA <50 copies per mL. (B) Incidence of new AIDS event. (C) Death rate.
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The median year of start of antiretroviral therapy was 2000 
(1998–2001) and the median year of TCVF was 2005 
(2003–2006), which was a median of 4·3 years (2·7–6·2) 
after the start of antiretroviral therapy. 892 (36%) of 2476 
patients started on two NRTIs and one NNRTI, 679 (27%) 
received two NRTIs and one protease inhibitor, 295 (12%) 
received two NRTIs and one ritonavir-boosted protease 
inhibitor, 123 (5%) received three NRTIs, and 487 (20%) 
received other combinations. Table 1 lists characteristics 
of individuals in follow-up in 2000–09. Notably, the 
proportion of people receiving at least one new drug (ie, 
atazanavir, darunavir, enfuvirtide, etravirine, maraviroc, 
raltegravir, or tipranavir) rose from 0% in 2000 to 52% 
in 2009. Few individuals received at least two of these 
drugs (<1% in 2003 to 11% in 2009). In 2009, 253 (32%) of 
2476 individuals were receiving atazanavir, 117 (15%) were 
receiving darunavir, 92 (12%) were receiving raltegravir, 
and 35 (4%) were receiving etravirine. The proportion of 
people not on antiretroviral therapy remained low for all 
years, but decreased from three (7%) of 41 people in 2000 
to 28 (4%) of 795 in 2009.
We obtained data for 25 685 measurements of plasma 
viral load after TCVF, with a median of eight measure-
ments (IQR four to 15) per person, of which 9564 (37%) 
were fewer than 50 copies per mL. The proportion of 
patients with virological response after TCVF increased 
from 19·5% for people followed up in 2000 to 57·9% in 
2009 (p<0·0001; fi gure).
1 year after TCVF, the estimated proportion of parti-
cipants with virological response was 17·1% in those who 
had TCVF in 2000 and 49·2% in those who had TCVF 
in 2008. Irrespective of the year of TCVF (see 
webappendix), people followed up to the most recent 
calendar years had the best outcomes.
n Univariable analysis Multivariable analysis
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Year <0·0001 <0·0001
2000–02 1792 (7%) 0·29 (0·22–0·38) ·· 0·27 (0·20–0·36) ··
2003 1882 (7%) 0·41 (0·33–0·51) ·· 0·40 (0·32–0·50) ··
2004 2746 (11%) 0·65 (0·56–0·74) ·· 0·63 (0·55–0·73) ··
2005 3524 (14%) 1 (reference) ·· 1 (reference) ··
2006 4435 (17%) 1·18 (1·06–1·32) ·· 1·18 (1·06–1·33) ··
2007 4695 (18%) 1·65 (1·46–1·87) ·· 1·65 (1·46–1·88) ··
2008 4756 (19%) 2·28 (2·00–2·60) ·· 2·29 (2·00–2·62) ··
2009 1855 (7%) 2·82 (2·39–3·33) ·· 2·79 (2·35–3·32) ··
Group <0·0001 <0·0001
Men who have sex with men 7911 (31%) 1 (reference) ·· 1 (reference) ··
Heterosexual men 5266 (20%) 0·77 (0·66–0·91) ·· 0·77 (0·64–0·93) ··
Heterosexual women 6337 (25%) 0·67 (0·57–0·78) ·· 0·63 (0·52–0·75) ··
Injecting-drug users 3473 (14%) 0·71 (0·59–0·86) ·· 0·81 (0·65–1·01) ··
Other or unknown 2698 (10%) 0·90 (0·73–1·11) ·· 0·95 (0·75–1·20) ··
Age at TCVF (years) 0·013 0·59
16–29 2940 (12%) 0·83 (0·67–1·01) ·· 0·95 (0·74–1·23) ··
30–39 11 307 (44%) 1 (reference) ·· 1 (reference) ··
40–49 8255 (32%) 1·12 (0·98–1·27) ·· 1·02 (0·88–1·18) ··
≥50 3183 (12%) 1·16 (0·97–1·39) ·· 1·15 (0·92–1·42) ··
Drugs failed by date of TCVF 0·28 0·31
≤4 4059 (16%) 1·17 (0·98–1·41) ·· 1·23 (0·98–1·53) ··
5 6185 (24%) 1·13 (0·96–1·33) ·· 1·03 (0·85–1·24) ··
6 8222 (32%) 1·11 (0·96–1·29) ·· 1·07 (0·89–1·27) ··
≥7 7219 (28%) 1 (reference) ·· 1 (reference) ··
AIDS present before TCVF (yes vs no) Yes 10 800 (42%);
no 14 885 (58%)
0·99 (0·88–1·12) 0·90 1·15 (0·99–1·32) 0·061
Never achieving viral load <50 copies per mL before TCVF 
(yes vs no)
Yes 9813 (38%);
no 15872 (62%)
0·42 (0·37–0·48) <0·0001 0·62 (0·53–0·73) <0·0001
Median viral load at TCVF (per log10 copies per mL increase) 4·0 (3·2–4·8) 0·75 (0·70–0·80) <0·0001 0·90 (0·83–0·98) 0·013
Median CD4 cell count at TCVF* (per 100 cells per μL increase) 269 (140–416) 1·13 (1·10–1·16) <0·0001 1·06 (1·03–1·10) 0·0002
Data are number of viral load measurements (%) or median (IQR), unless otherwise stated. TCVF=triple-class virological failure. *Missing for 82 (0·3%) of 25 685 included 
viral load measurements.
Table 2: Predictors of virological response (viral load <50 copies per mL) in individuals with TCVF
See Online for webappendix
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Table 2 shows the results of the univariable and 
multivariable models for prediction of virological 
response. In the multivariable model, male and female 
heterosexuals and injecting drug users were less likely to 
achieve virological response than were men who have sex 
with men. Individuals with a lower viral load and a higher 
CD4 cell count at time of TCVF were more likely to 
achieve virological response, whereas people who had 
never achieved virological response before TCVF were 
less likely to achieve it. Finally, patients who were followed 
later (ie, closer to 2009) were more likely to achieve viral 
suppression. Notably, there was no overlap between the 
CI of the odds ratios for 2008–09 and those for 2006–07. 
Results were robust when we used an auto regressive 
covariance matrix instead of an exchangeable one 
(webappendix).
In 7777 patient-years of follow-up 311 people had a new 
AIDS event. The crude incidence of AIDS-defi ning event 
decreased from 7·7 per 100 patient-years between 
2000 and 2002 to 2·3 in 2008 and 1·2 in 2009 (p<0·0001; 
fi gure). This signifi cant trend was strongest in 2008 and 
2009 in univariable and multivariable analyses (table 3). 
People with a higher viral load, a lower CD4 cell count, or 
a previous AIDS event at time of TCVF, or without 
virological response before TCVF were more likely to 
have a new AIDS event.
160 people died in 7568 patient-years of follow-up. The 
crude rate of death decreased from 4·0 per 100 patient-
years between 2000 and 2002 to 1·9 in 2007 and 1·4 in 
2008 (p=0·023; fi gure). Injecting drug users, young 
people (<30 years old), older people (≥50 years old), and 
those who had had an AIDS event were more likely to die 
(table 4). People with a higher CD4 cell count at time of 
TCVF were less likely to die than were those with a low 
CD4 cell count. After accounting for these variables, the 
trend noted over time (p=0·023) was no longer signifi cant 
(p=0·22). To account for the fact that injecting drug users 
are more likely to die from causes not infl uenced by HIV 
infection and its treatment, we did a post-hoc sensitivity 
analysis excluding this group. In this analysis, 120 people 
Univariable analysis Multivariable analysis
Incidence rate ratio (95% CI) p value Incidence rate ratio (95% CI) p value
Year <0·0001 <0·0001
2000–02 1·58 (1·03–2·41) ·· 1·30 (0·85–2·00) ··
2003 1·59 (1·05–2·41) ·· 1·47 (0·97–2·24) ··
2004 1·08 (0·71–1·65) ·· 1·04 (0·68–1·58) ··
2005 1 (reference) ·· 1 (reference) ··
2006 0·76 (0·51–1·12) ·· 0·81 (0·55–1·21) ··
2007 0·76 (0·52–1·12) ·· 0·86 (0·58–1·27) ··
2008 0·47 (0·30–0·73) ·· 0·56 (0·36–0·87) ··
2009 0·25 (0·13–0·49) ·· 0·31 (0·16–0·62) ··
Group 0·54 0·98
Men who have sex with men 1 (reference) ·· 1 (reference) ··
Heterosexual men 1·14 (0·83–1·58) ·· 0·91 (0·65–1·26) ··
Heterosexual women 1·08 (0·79–1·48) ·· 0·98 (0·71–1·35) ··
Injecting-drug users 1·32 (0·93–1·86) ·· 1·00 (0·71–1·43) ··
Other or unknown 1·27 (0·86–1·87) ·· 0·96 (0·65–1·42) ··
Age at TCVF (years) 0·45 0·80
16–29 0·99 (0·69–1·42) ·· 1·00 (0·69–1·44) ··
30–39 1 (reference) ·· 1 (reference) ··
40–49 0·84 (0·65–1·08) ·· 0·90 (0·69–1·17) ··
≥50 0·81 (0·56–1·17) ·· 0·86 (0·59–1·27) ··
Drugs failed by date of TCVF 0·68 0·30
≤4 1·10 (0·78–1·55) ·· 1·19 (0·84–1·68) ··
5 0·89 (0·65–1·23) ·· 0·89 (0·65–1·23) ··
6 1·04 (0·78–1·39) ·· 1·16 (0·86–1·54) ··
≥7 1 (reference) ·· 1 (reference) ··
AIDS present before TCVF (yes vs no) 2·00 (1·60–2·50) <0·0001 1·64 (1·30–2·06) <0·0001
Never achieving viral load <50 copies per mL before TCVF (yes vs no) 2·22 (1·78–2·78) <0·0001 1·46 (1·16–1·85) 0·0016
Median viral load at TCVF (per log10 copies per mL increase) 1·79 (1·59–2·01) <0·0001 1·35 (1·19–1·54) <0·0001
Median CD4 cell count at TCVF* (per 100 cells per μL increase) 0·65 (0·60–0·70) <0·0001 0·74 (0·68–0·80) <0·0001
TCVF=triple-class virological failure. *Missing for 28 (0·4%) person-years of follow-up.
Table 3: Predictors of new AIDS event12 after TCVF
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died during 6477 years of follow-up. In these analyses, 
the decrease in the risk of death between 2000 and 
2008 was signifi cant in the univariable analysis 
(p=0·0045) and neared signifi cance in the multivariable 
analysis (p=0·064).
Discussion
Between 2000 and 2009, the proportion of people who 
had virological response after TCVF improved 
substantially, and there was a concomitant decrease in 
AIDS incidence. However, we did not note an overall 
decrease in mortality.
Our aim was to assess whether there was an improvement 
in outcomes for people who had TCVF in the past decade, 
and we adjusted our models only for variables measured 
at the time of TCVF because such characteristics might 
change with time and aff ect outcomes. With this type of 
analysis we were able to show if there was, or not, a true 
trend in time. We chose not to analyse the extent to which 
the measures of improvements in antiretroviral therapy 
could statistically explain (ie, remove) the positive trends. 
This choice was made because we did not have measures 
of drug adherence or good measures of the presence of 
viral drug resistance. However, we intend in the future to 
merge data for viral resistance in our study population to 
assess trends in detected resistance. Because of our 
objective, we do not think any other independent variables 
available at TCVF should have been added in the models. 
For example, CD4 cell count at treatment initiation, which 
might have changed dependent on the year and might be 
associated with any one of the three outcomes, would be 
strongly correlated with CD4 cell counts at TCVF, so 
would not be an independent factor.
The positive trends that we noted probably relate to 
improvements in adherence and management of 
resistance, increasing availability of new drugs within 
existing classes (such as the protease inhibitor darunavir 
and the NNRTI etravirine), and increasing availability of 
drugs from new classes, making new regimens with 
minimal cross-resistance possible.13 The trend for an 
Univariable analysis Multivariable analysis
Incidence rate ratio (95% CI) p value Incidence rate ratio (95% CI) p value
Year* 0·023 0·22
2000–02 1·59 (0·90–2·80) ·· 1·40 (0·79–2·51) ··
2003 0·64 (0·30–1·35) ·· 0·61 (0·29–1·30) ··
2004 0·97 (0·55–1·73) ·· 0·93 (0·52–1·65) ··
2005 1 (reference) ·· 1 (reference) ··
2006 0·83 (0·50–1·39) ·· 0·88 (0·53–1·47) ··
2007 0·74 (0·44–1·24) ·· 0·83 (0·50–1·39) ··
2008 0·55 (0·32–0·97) ·· 0·63 (0·36–1·11)) ··
Group 0·0005 0·0008
Men who have sex with men 1 (reference) ·· 1 (reference) ··
Heterosexual men 1·04 (0·64–1·68) ·· 0·78 (0·47–1·27) ··
Heterosexual women 0·93 (0·57–1·50) ·· 0·91 (0·56–1·49) ··
Injecting-drug users 2·15 (1·39–3·33) ·· 2·03 (1·29–3·19) ··
Other or unknown 1·80 (1·08–2·98) ·· 1·33 (0·80–2·23) ··
Age at TCVF (years) 0·012 0·0021
16–29 1·59 (0·97–2·61) ·· 1·80 (1·09–2·97) ··
30–39 1 (reference) ·· 1 (reference) ··
40–49 1·31 (0·90–1·92) ·· 1·37 (0·93–2·01) ··
≥50 2·05 (1·32–3·19) ·· 2·34 (1·48–3·70) ··
Drugs failed by date of TCVF 0·91 0·68
≤4 0·84 (0·51–1·39) ·· 0·86 (0·52–1·43) ··
5 0·93 (0·60–1·43) ·· 0·90 (0·59–1·40) ··
6 0·98 (0·66–1·46) ·· 1·12 (0·75–1·67) ··
≥7 1 (reference) ·· 1 (reference) ··
AIDS present before TCVF (yes vs no) 2·41 (1·75–3·31) <0·0001 1·90 (1·37–2·65) 0·0001
Never achieving viral load <50 copies per mL before TCVF (yes vs no) 1·68 (1·23–2·30) 0·0010 1·18 (0·85–1·64) 0·32
Median viral load at TCVF (per log10 copies per mL increase) 1·42 (1·21–1·67) <0·0001 1·07 (0·90–1·28) 0·46
Median CD4 cell count at TCVF† (per 100 cells per μL increase) 0·66 (0·59–0·74) <0·0001 0·71 (0·63–0·80) <0·0001
*Data censored on Jan 1, 2009, to avoid potential incomplete data reporting for some cohorts. †Missing for 27 (0·4%) person-years of follow-up. TCVF=triple-class 
virological failure.
Table 4: Predictors of death after TCVF
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improved virological outcome was strongest in 2008 and 
2009, shortly after four new drugs were approved in 
Europe (darunavir in February, 2007, maraviroc in 
September, 2007, raltegravir in December, 2007, and 
etravirine in August, 2008).
Our results suggest eff ectiveness at a routine clinical 
population scale of new antiretroviral drugs in terms of 
morbidity and rates of virological suppression (panel). In 
particular, because the risk of death did not seem to 
increase and was perhaps decreasing in individuals who 
do not use injecting drugs, this study supports the notion 
that any adverse eff ects of these new drugs on mortality 
are outweighed by the benefi ts. The positive trends we 
reported between 2000 and 2009 in this study probably 
result from improvements in tolerability and ease of use 
of drug regimens,14,15 and in the availability of drugs with 
non-overlapping resistance profi les. Our results are 
consistent with recent studies indicating that the 
proportion of overall clinic populations with suppressed 
viral load has increased with time.16–18
Although we suggest there was a trend towards a 
decline in mortality, this fi nding was not signifi cant in 
multivariable analyses; however, there was a substantial 
decrease in the rate of new cases of AIDS. The reason for 
this diff erence might be the small sample size 
(160 endpoints for death vs 311 for AIDS). In the analysis 
excluding injecting drug users, the time trend for a 
decline in death rate approached signifi cance in the 
multivariable analysis even though its power was smaller 
than in the overall analysis (120 endpoints instead of 160). 
Another reason for the absence of a signifi cant response 
in death rate might be because, between 2000 and 2009, 
a comparatively small and diminishing proportion of 
deaths in those with TCVF was caused by AIDS.19,20 Thus, 
there is less room for improvement through increased 
virological control. Nevertheless, there is evidence that 
HIV increases the risk of several serious non-AIDS 
conditions21 so some decrease with time in death rates 
from non-AIDS causes would be expected. Such disorders 
might relate to HIV-induced immune activation and 
infl ammation, which generally persist in the fi rst few 
years after virological control, and could partly explain 
the lesser trend that we noted for risk of death.22,23 
Furthermore, long-term adverse events might have 
contributed to the weak trend. We are aware that not all 
cohorts link their data with national death registries, 
which might result in an underestimation of mortality. A 
long delay in ascertainment of deaths could lead to 
overestimation of any positive trends in mortality. By 
contrast, ascertainment of AIDS should be high because 
this outcome is chiefl y diagnosed at the clinics 
themselves. This reasoning is why we censored data on 
Jan 1, 2009, for death and report results about death to 
2008. Nevertheless, this issue cannot explain weakness 
of the trend for death.
A low CD4 cell count at TCVF was associated with low 
probability of virological success and high risk of new 
AIDS events and death. This result, once again, 
emphasises the importance of maintenance of a healthy 
CD4 cell count and of an early identifi cation and 
treatment of HIV infection.
Despite improvements, viral loads cannot be sup-
pressed for some people with TCVF. This eff ect is 
probably caused by insuffi  cient adherence to drug 
regimens rather than presence of a virus resistant to all 
drugs.24 However, some people do have viruses with 
resistance to all drugs available in 2009.25,26
Whether the improving trend, or even the current rate 
of viral suppression in 2009, can be sustained in the 
future is unclear. Continued improvement will likely 
need continued development of new drugs, which are 
active against virus with resistance to existing drugs.
COHERE accumulates data from cohorts in most 
countries in western Europe, and includes data for more 
than 70% of the patients in care in France, the 
Netherlands, and Switzerland, and 50% of such patients 
in the UK. Individuals from these four countries make 
up two-thirds of our dataset and thus we believe that our 
results are representative of the trends for these countries, 
and probably for western Europe as a whole. However, 
we cannot exclude the possibility that, in these countries, 
clinics contributing to the cohorts have a higher standard 
of care and perhaps a greater level of viral suppression 
than do non-participating clinics.
Panel: Research in context
Systematic review
Previous studies that investigated virological or clinical 
outcomes in people who had virological failure on the original 
three classes of antiretroviral drugs dealt mainly with people 
who had started antiretroviral therapy with one or two 
drugs;1–4 however, this group is now of decreased relevance. We 
searched PubMed for articles published in any language 
between January, 2004, and June, 2011, that investigated 
virological or clinical outcomes (see webappendix) in people 
with triple-class virological failure who started treatment when 
combined therapy with three or more drugs had become the 
norm (1998); we identifi ed only one such study.9 Because of its 
small size (167 people with triple-class virological failure), this 
study had a little power to assess trends of virological and 
clinical outcomes after triple-class virological failure.
Interpretation
In western Europe, there has been a striking improvement of 
virological status of people with triple-class virological failure 
between 2000 and 2009 in routine clinical practice, especially 
since 2008, and an accompanying decrease in the rate of 
AIDS. This eff ect is probably largely due to the fact that, in the 
same period, several drugs have become available that are 
easier to use and better tolerated than were existing drugs, 
and tend to be active against virus resistant to typical 
fi rst-line and second-line drugs.
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Overall, we showed substantial improvements between 
2000 and 2009 in virological suppression in people who 
had virological failure to drugs from the three original 
classes of antiretrovirals, and accompanying decreases in 
rates of AIDS. We suggest that the set of available drugs 
is suffi  cient to enable construction of active regimens for 
most infected people. However, because previously 
untreated patients who start antiretroviral therapy from 
2011 will do so with drugs that are diff erent from those 
used in 1998–2001, drug resistance profi les will diff er in 
the future and thus there will be a continuing need for 
new drugs with non-overlapping resistance profi les.
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